amylase alpha 1C

Overview

Amylase alpha 1C (AMY1C) is a member of the amylase family of enzymes, which play a crucial role in carbohydrate metabolism by catalyzing the hydrolysis of starch into sugars. This enzyme is primarily produced in the salivary glands and pancreas, contributing to the digestion of carbohydrates in the human body. The activity of AMY1C is significant in the context of metabolic diseases, particularly type 2 diabetes, where the regulation of carbohydrate absorption is critical. Inhibiting AMY1C can slow down the digestion of carbohydrates, thereby reducing postprandial blood glucose levels, which is a therapeutic target for managing diabetes.

Focus of Latest Publications

Recent studies have extensively investigated inhibition of α-amylase as a therapeutic approach for managing glucose metabolism and obesity-related metabolic dysfunction. A diverse array of compounds have demonstrated inhibitory activity against this enzyme, including natural plant-derived polyphenols such as proanthocyanidins from cranberry extract, phenolic compounds from Fagonia cretica and hawthorn leaves, and essential oils from Boswellia serrata, as well as engineered nanoparticle systems—including zinc oxide nanoparticles synthesized from pomegranate husk extract and ascorbic acid-functionalized zinc oxide nanoparticles (ZnO-AA NPs). Additionally, novel synthetic compounds (triazole oxime derivatives and bismuth-based hybrid materials) and selenized polysaccharide nanoparticles have demonstrated potent inhibitory capacity, with several outperforming the reference antidiabetic drug acarbose in direct comparisons.

The principal mechanism of action across these studies involves delaying intestinal carbohydrate digestion and glucose absorption. Proanthocyanidin-rich cranberry extract improved glycemia and glucose tolerance in established diet-induced obesity through α-amylase inhibition coupled with selective remodeling of the gut microbiota, particularly expansion of Akkermansia muciniphila. Nanoparticle formulations demonstrated enhanced inhibitory efficacy relative to free compounds through improved cellular uptake and bioavailability; selenized polysaccharide nanoparticles achieved glycemic control equivalent to substantially higher doses of the unconjugated compound in streptozotocin-induced diabetic mice. Molecular docking studies identified specific phytochemical constituents—quercetin, luteolin, catechin, gallic acid, and trans-caffeic acid—as primary mediators of α-amylase binding, with binding affinities frequently exceeding reference inhibitors.

The α-amylase inhibitory effects observed across these structurally diverse compound classes—natural polyphenols, synthetic molecules, and nanoparticulate systems—consistently correlated with broader antioxidant activity and improved metabolic parameters. Extraction methodology and plant organ source significantly influenced inhibitory potency, reflecting compositional variation in bioactive phenolics and flavonoids. These findings position α-amylase inhibition as a validated and multifunctional therapeutic target applicable to natural product-based therapeutics, nanotechnology-enabled drug delivery, and synthetic molecular design for addressing type 2 diabetes and obesity-associated complications.

Key Publications

• NEWJun Proanthocyanidin-Rich Cranberry Extract Lowers Glycemia in Established Obesity by Delaying Glucose Absorption. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42328893): "Mechanistically, PRCE inhibited α-amylase activity and delayed early intestinal glucose absorption."
• NEWJun Overcoming cellular secretion bottlenecks: advanced secretion engineering and molecular tailoring for next-generation microbial α-amylases with enhanced industrial performance. (World journal of microbiology & biotechnology, 2026, PMID 42329468): "α-amylases are indispensable industrial biocatalysts, yet their recombinant production faces significant biochemical and cellular bottlenecks."
• Jun Bismuth hybrid halide with dual inhibition against α-amylase and acetylcholinesterase probed by structural, vibrational, and theoretical analysis. (Journal of materials chemistry. B, 2026, PMID 42171151): "Most significantly, enzymatic inhibition assays demonstrated the compound's exceptional dual bioactivity. It exhibited potent inhibition against acetylcholinesterase (AChE, IC50 = 1.96 ± 0.1 mM) and α-amylase (IC50 = 0.27 ± 0.014 mM),"
• Jun Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Profiling, Antioxidant, Antibacterial, and Antidiabetic Properties of Fagonia cretica L.: Insights From In Vitro and In Silico Approaches. (ChemistryOpen, 2026, PMID 42168772): "Inhibition of α-amylase was observed, indicating weak to modest metabolic benefits, though less potent than acarbose."
• May Green synthesis of ZnO nanoparticles using pomegranate husk extract: comparative evaluation of antioxidant, enzyme inhibition, and cytotoxic properties. (Artificial cells, nanomedicine, and biotechnology, 2026, PMID 42142531): "Both types of ZnO NPs demonstrated notable antioxidant activity (>62% scavenging in DPPH and ABTS assays) and strong inhibitory effects against pancreatic lipase and α-amylase (>70%), comparable to standard drugs such as orlistat and acarbose."
• May Ultrasound-Assisted Extraction of Free and Bound Phenolics from Hawthorn (Crataegus azarolus) Leaves and their Antioxidant and Antidiabetic Activities. (Plant foods for human nutrition (Dordrecht, Netherlands), 2026, PMID 42141147): "Both fractions inhibited α-amylase and α-glucosidase, demonstrating their in vitro enzyme inhibitory potential."
• May Comparative metabolic profiling, enzyme inhibitory activities, and in-silico analysis of the hexane extract and the hydrodistilled oil of Boswellia serrata. (PloS one, 2026, PMID 42102034): "The HE extract was only more active on α-amylase compared to the oil."
• May Organ-Specific Phytochemical Composition and Bioactivity Profiling of Chaerophyllum aksekiense: A Multiassay Antioxidant, Enzyme Inhibition, and Correlation-Based Evaluation. (ChemistryOpen, 2026, PMID 42051056): "roots were most active against α-amylase, and leaves against α-glucosidase."
• Apr Formulation and characterization of ascorbic acid-based zinc oxide nanoparticles for assessing antidiabetic and neuroprotective effects in STZ-induced diabetic rats. (Artificial cells, nanomedicine, and biotechnology, 2026, PMID 42047278): "In vitro, ZnO-AA NPs showed dose-dependent inhibition of α-amylase and α-glucosidase."
• May Integrated Phytochemical Profiling and Multifunctional Bioactivities of Bellis annua Extracts Obtained by Distinct Extraction Techniques. (ChemistryOpen, 2026, PMID 42012914): "Enzyme inhibition assays revealed method-specific differences: MAC showed the most pronounced acetylcholinesterase and α-amylase inhibition, whereas SOE demonstrated superior tyrosinase inhibition."